An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary Therapy

• Published in: Journal of clinical oncology Vol. 25; no. 24; pp. 3615 - 3620
• Main Authors: LIU, Ping-Yu, ALBERTS, David S, MONK, Bradley J, BRADY, Mark, MOON, James, MARKMAN, Maurie
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 20.08.2007; Lippincott Williams & Wilkins
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomarkers, Tumor - blood; CA-125 Antigen - blood; Disease Progression; False Positive Reactions; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Prognosis; Tumors; Human; Carbohydrate antigen; Tumor associated antigen; Ovary cancer; Treatment efficiency; Tumoral marker; Malignant tumor; Female genital diseases; Ovarian diseases; Signal transduction; Cancerology; Maintenance treatment; Primary; Tumor progression; CA 125 antigen; Early

For ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy, we tested the predictive value of the following early signal of progressive disease (EPD) criterion based on serum CA-125: for patients with CA-125 nadir <or= 10 U/mL, a confirmed valu...